Pharmaceuticals News and Research

RSS

First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the first patient has been enrolled in the Company's pivotal Phase 3 clinical study, study 007, of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN).

3 Aug 2015

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced a collaboration with Galectin Therapeutics to use the BreathID test to monitor patients in a Phase II study evaluating GR-MD-02.

3 Aug 2015

Charleston Laboratories begins Phase 1 study on CL-H1T migraine drug candidate

Charleston Laboratories, Inc., an emerging specialty pharmaceutical company, announced initiation of its second clinical development program with a Phase 1 study on its migraine drug candidate, CL-H1T.

3 Aug 2015

Shire acquires Foresight Biotherapeutics for $300 million

Shire plc announced today that it has acquired New York-based, privately held Foresight Biotherapeutics Inc. for $300 million.

3 Aug 2015

Soligenix signs $10M equity purchase agreement with accredited institutional investors

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has entered into a $10 million equity purchase agreement with accredited institutional investors, Kodiak Capital Group, LLC, Kingsbrook Opportunities Master Fund LP and River North Equity, LLC.

3 Aug 2015

TWi Biotechnology gets notice of patent allowance covering use of AC-201 drug in diabetes treatment

TWi Biotechnology, Inc., today announced that it has received Notices of Allowance for AC-201, TWi Biotechnology's lead drug candidate, from the European Patent Office and the Patent Office of the Russian Federation for patent applications numbered 11766702.2-1460 and 2012147449, respectively.

3 Aug 2015

Sorrento to develop and market monoclonal antibodies for North American, European and Japanese market

Sorrento Therapeutics, Inc. announced today that it has entered into an exclusive licensing agreement to develop and commercialize multiple prespecified and undisclosed biosimilar or biobetter antibodies from Mabtech Limited, a holding company for premier antibody development and manufacturing companies in China.

3 Aug 2015

Isis Pharmaceuticals, AstraZeneca to develop antisense therapies for cardiovascular, metabolic, renal diseases

AstraZeneca and Isis Pharmaceuticals, Inc. today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases.

3 Aug 2015

Teen scientist finds solution to tackle water quality issues

For some of us it was an exciting time of creative experimentation. For others it was a time of botched and badly displayed data. For 16-year-old Maria Elena Grimmett, it's a blast. And she isn't peddling baking soda and vinegar volcanoes. Grimmett is tackling serious water quality issues that threaten the health of rivers, streams and groundwater. When she was just 14 years old, Grimmett was the youngest person published in the Journal of Environmental Quality.

31 Jul 2015

John T. Spitznagel attains recognition in Strathmore's Who's Who for contributions in Healthcare Sales and Marketing

John T. Spitznagel of Glen Burnie, Maryland, has attained recognition in Strathmore's Who's Who for his contributions and achievements in the field of Healthcare Sales and Marketing. On Friday, July 31, 2015, he will be honored with a Times Square, New York appearance.

31 Jul 2015

U.S. Navy leads government category in annual ranking of patent portfolios

Predicting the risk of pirate attacks on vital shipping lanes could soon be easier, thanks to a data system that's just one of 364 technologies patented by the U.S. Navy (DoN) in 2014.

31 Jul 2015

Scientists produce functional liver cells from human embryonic and genetic engineered stem cells

The liver plays a critical role in human metabolism. As the gatekeeper of the digestive track, this massive organ is responsible for drug breakdown and is therefore the first to be injured due to overdose or misuse. Evaluating this drug-induced liver injury is a critical part of pharmaceutical drug discovery and must be carried out on human liver cells. Regretfully, human liver cells, called hepatocytes, are in scarce supply as they can only be isolated from donated organs.

31 Jul 2015

Takeda completes post-marketing commitment and data submission for pioglitazone containing medicines

Takeda Pharmaceutical Company Limited today announced the completion of the study to fulfill the post-marketing commitment and submissions of data to regulatory authorities from the Pan European Multi-Database Bladder Cancer Risk Characterization Study, a large (n= 112,674), multi-database retrospective matched cohort study, conducted in four European countries, for pioglitazone containing medicines, including ACTOS with up to 10 years of follow-up.

31 Jul 2015

NEJM publishes positive clinical results from Phase 2 clinical study of volanesorsen

Isis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, and Akcea Therapeutics, its wholly owned subsidiary, announced today that The New England Journal of Medicine (NEJM) has published positive clinical results from a Phase 2 clinical study evaluating volanesorsen (formerly ISIS-APOCIII Rx) in patients with very high to severely high triglycerides.

30 Jul 2015

Blocking the expression of certain gene reduces excessive fat in patients

By blocking the expression of a certain gene in patients, University of Montreal researchers have contributed to the demonstration of great decreases in the concentration of triglycerides in their blood, even in various severe forms of hypertriglyceridemia and regardless of the base values or the treatment the patient usually receives.

30 Jul 2015

Protecting gastrointestinal system during radiation or chemotherapy allows patients to tolerate cancer treatments

The stem cells in our gut divide so fast that they create a completely new population of epithelial cells every week. But this quick division is also why radiation and chemotherapy wreak havoc on the gastrointestinal systems of cancer patients - such therapies target rapidly dividing cells.

30 Jul 2015

Researchers demonstrate direct connection between NOX proteins and liver fibrosis

Researchers at the University of California, San Diego School of Medicine have demonstrated a direct connection between two signaling proteins and liver fibrosis, a scarring process underlying chronic liver disease, the 12th leading cause of death in the United States.

30 Jul 2015

World Health Organization recognizes unique pharmacological nature of Can-Fite's CF101, grants new generic name

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced that the World Health Organization's International Nonproprietary Name group has accepted the proposed generic name "piclidenoson" for its lead drug candidate, CF101.

29 Jul 2015

GE Healthcare to invest more than $1 billion over five years in enhanced training for healthcare professionals

In developed countries like the U.S., Europe and parts of Asia, healthcare leaders are trying to optimize efficiency, systems integration, data analytics and achieve greater productivity. In emerging economies, enabling access to affordable, basic primary care is often the most pressing concern. Healthcare systems around the world face a wide range of difficult challenges. All could benefit from training and education solutions focused specifically on their particular needs.

29 Jul 2015

PDL BioPharma signs revenue interest assignment agreement with ARIAD Pharmaceuticals

PDL BioPharma, Inc. today announced that it has entered into a revenue interest assignment agreement (the "Agreement") in which it has agreed to provide ARIAD Pharmaceuticals, Inc. with up to $200 million in revenue interest financing in exchange for royalties on the net revenues of Iclusig (ponatinib).

29 Jul 2015

Pharmaceuticals News and Research

First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Charleston Laboratories begins Phase 1 study on CL-H1T migraine drug candidate

Shire acquires Foresight Biotherapeutics for $300 million

Soligenix signs $10M equity purchase agreement with accredited institutional investors

TWi Biotechnology gets notice of patent allowance covering use of AC-201 drug in diabetes treatment

Sorrento to develop and market monoclonal antibodies for North American, European and Japanese market

Isis Pharmaceuticals, AstraZeneca to develop antisense therapies for cardiovascular, metabolic, renal diseases

Teen scientist finds solution to tackle water quality issues

John T. Spitznagel attains recognition in Strathmore's Who's Who for contributions in Healthcare Sales and Marketing

U.S. Navy leads government category in annual ranking of patent portfolios

Scientists produce functional liver cells from human embryonic and genetic engineered stem cells

Takeda completes post-marketing commitment and data submission for pioglitazone containing medicines

NEJM publishes positive clinical results from Phase 2 clinical study of volanesorsen

Blocking the expression of certain gene reduces excessive fat in patients

Protecting gastrointestinal system during radiation or chemotherapy allows patients to tolerate cancer treatments

Researchers demonstrate direct connection between NOX proteins and liver fibrosis

World Health Organization recognizes unique pharmacological nature of Can-Fite's CF101, grants new generic name

GE Healthcare to invest more than $1 billion over five years in enhanced training for healthcare professionals

PDL BioPharma signs revenue interest assignment agreement with ARIAD Pharmaceuticals

Event guide: World ADC London eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring